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ABSTRACT
Objective: Chronic heart failure (CHF) is a chronic multisystem disorder associated with a myriad of metabolic disturbances. Moreover, CHF may 
adversely affect bone metabolism and induce a severe bone loss, increasing susceptibility to fractures and osteoporosis. This study investigates the 
effect of combined calcium with Vitamin D3 supplement called “calcemin advance” and calcitonin in the prophylaxis and treatment of osteopenia and 
osteoporosis in patients with coronary heart disease (CHD) complicated by CHF with the establishment of their influence on the bone mineral density 
(BMD).
Methods: A total of 59 patients with CHD complicated by CHF. Interventions: The physical examination findings, dual-energy X-ray absorptiometry 
findings, and treatment results were assessed.
Results: The results of the calcemin advance usage in patients with osteopenic changes showed a positive dynamics of the studied parameters, 
both in the lumbar spine and in the femoral bone. In patients with osteoporosis, the usage of osteoprotective therapy (calcemin advance+miacalcic) 
contributed to the increasing of BMD in the lumbar spine and in the femoral bone versus patients who received only combined calcium with Vitamin 
D3 supplement.
Conclusions: Our results suggest that bone density screening could be recommended in patients with prevalent CHF. Moreover, the results of our 
investigation substantiate the necessity and effectiveness of osteoprotective therapy in patients with CHF with osteoporosis by calcitonin (Miacalcic), 
in combination with combined calcium and Vitamin D3 supplement (calcemin advance), and by only calcemin advance - in patients with CHF and 
osteopenia.
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INTRODUCTION
Cardiovascular diseases (CVDs) remain the biggest cause of deaths 
worldwide [1-3]. It accounts for 45.1% of mortality, the majority of this in 
the form of coronary heart disease (CHD) [4]. In 2015, 19.9 million CVDs 
deaths occurred (one-third of all global deaths), and 423 million people had 
prevalent CVDs (∼1 in 17 of the global population) [5,6]. By 2020, 7 of 10 
deaths in developing countries are predicted to be due to noncommunicable 
diseases - the majority of which would be due to CVDs [7].
Chronic heart failure (CHF) is a complex clinical syndrome in which 
abnormal heart function results in, or increases the subsequent risk 
of, clinical symptoms and signs of reduced cardiac output, and/or 
pulmonary or systemic congestion at rest or with stress [8]. CHF is, 
nowadays, an important health problem. Not only is CHF associated 
with high use of resources and health-care cost but also the prevalence 
of heart failure is increasing due to better care and treatment and to the 
aging of the population [9]. The prevalence of CHF is ~2% of the general 
population in the developed countries, increasing to ~10% among 
people >70 years of age; moreover, the prevalence increased with age 
in both men and women. Worldwide, the number of patients with heart 
failure has reached 22.5 million [10].
CHF is a chronic multisystem disorder associated with a myriad of 
metabolic disturbances. Moreover, CHF may adversely affect bone 
metabolism and induce a severe bone loss, increasing susceptibility 
to fractures and osteoporosis [11]. It should be noted that CHF and 
osteoporosis are often diagnosed in the same patient [12].
Therefore, both CHF and osteoporosis are common causes of loss of 
function and independence and have become a heavy burden on the 
health-care system. Our previous studies showed that structural and 
functional changes in the bone tissue of the lumbar spine were found in 
75.9% of patients with Stage 1 of CHF caused by ischemic heart disease: 
64.4% of patients had osteopenic syndrome and 11.5% - osteosclerotic 
changes. In 75.8% of CHF patients, we have found structural and functional 
changes in the bone tissue of proximal right femur [13]. Structural and 
functional changes of bone tissue of the lumbar spine have been found in 
49.2% of patients with CHD complicated by Stage II-A CHF, in particular, I 
stage of osteopenia – in 44.6%, II stage of osteopenia - in 27.7%, III stage 
of osteopenia - in 10.8%, and osteoporosis - in 16.9% [14].
Objectives
This study aims to investigate the effect of combined calcium with 
Vitamin D3 supplement called “calcemin advance” and calcitonin in the 
prophylaxis and treatment of osteopenia and osteoporosis in patients 
with CHD complicated by CHF with the establishment of their influence 
on the bone mineral density (BMD).
METHODS
Subject selection
The study involved 59 patients with CHD complicated by CHF according 
to the classification by N.D. Strazhesko, V.H. Vasilenko and G.F. Lung 
(1935) at Ternopil University Hospital.
The average age of patients was 57.91±9.30 years. Their body mass 
index exceeded normal range (set at <25 kg/m2) and was in the range of 
subcompensated obesity - 28.04±2.12 kg/m2. Clinical characteristics of the 
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patients were as follows: The disease duration ranged from 2 to 20 years, 
the underlying disorder mainly was cardiosclerosis. In patients’ history was 
found bad habits: 16 - smoking, 4 - alcohol abuse, and 12 - caffeine abuse 
(4–5 cups of coffee per day). A history of fractures was found in 9 persons.
The patients did not have other severe comorbidities that could have 
caused changes in bone tissue. A total of 59 participants were used 
for this research work. Informed written consent was provided by 
all participants. Ethical approval was obtained from I. Horbachevsky 
Ternopil State Medical University Ethics Committee.
Diagnosis of CHD was confirmed using a set of characteristic 
anamnestic, clinical (typical angina attacks with physical and psycho-
emotional stress), biochemical (increased total cholesterol and total 
lipids levels), and electrocardiography (ST-segment depression below 
the baseline, T-wave inversion) data. To confirm the diagnosis, we also 
used data obtained during a physical examination, such as enlarged to 
the left heart boundaries, weakened sound of the top tone, stress of the 
second tone above the aorta, changes in blood pressure and heart rate.
To verify the diagnosis of heart failure we have used the main limiting factors 
of physical performance and clinical symptoms: Dyspnea, tachycardia, and 
fatigue after exertion. The final diagnosis of CHF with systolic dysfunction 
was given based on the results of echocardiography test.
Determination of BMD
Dual-energy X-ray absorptiometry is widely used for measuring BMD 
due to its recognized precision. The method utilizes two measurements, 
T-score and Z-score. The first one is calculated when the patient’s BMD 
is subtracted from mean BMD of a population of healthy young adults, 
matched. The T-score is calculated as a number of standard deviations 
(SDs); the patient’s measured BMD is above or below the mean for 
population of healthy 30-year adults, matched for sex and ethnicity. 
The Z-score is expressed in units of the population SD, but instead of 
comparing the patient’s BMD to the mean of the young adult population, 
it is compared with the mean BMD of a healthy population matched for 
age, sex, and ethnicity. In this study, we evaluated the scores according 
to the WHO guidelines (WHO, Geneva, 1994): BMD >1.2 g/sm2 is 
classified as osteosclerosis; a T-score ≥ −1 is regarded as normal, and 
T-score between −2.5 and −1 is classified as osteopenia [15].
Standard therapy for patients with CHF included the use of an 
angiotensin-converting enzyme inhibitor, β-adrenoblocker, diuretic, 
and cardiac glycoside according to the recommendations of the 
Ukrainian Association of Cardiologists for the diagnosis, treatment, and 
prevention of CHF. Patients’ therapy was as standardized as possible. 
Before the survey, patients did not receive antiresorptive drugs for the 
prophylaxis and treatment of osteoporosis.
To study the effects of the combined calcium with Vitamin D3 
supplement (calcemin advance) and calcitonin (Miacalcic) on bone 
tissue, the patients were distributed as follows. We have used Calcemin 
Advance (Sagmel, Inc. USA), which consists of calcium carbonate 
1312 mg, Vitamin D3 200 IU, magnesium oxide 40 mg, zinc oxide 
7.5 mg, copper 1.0 mg, and sodium borate 2.45 mg.
The 1st Group (12 persons) consisted of patients with normal BMD, 
which was carried out only standardized therapy.
The 2nd Group of patients (13 persons) received the same standardized 
therapy as the 1st Group, but there BMD was characterized by osteopenic 
changes.
The 3rd Group of patients (15 persons) with osteopenic changes, in 
addition to standard therapy, was prescribed combined calcium with 
Vitamin D3 supplement - calcemin advance. Calcemin advance therapy 
was performed for 3 months (1 tablet 2 times per day).
The 4th Group of patients (10 persons) received the same therapy as the 
third one, but changes in bone tissue were consistent with osteoporosis.
The 5th Group of patients (9 persons) with diagnosed osteoporosis 
received the same therapy as the 4th Group, and calcitonin (Miacalcic). 
Miacalcic (salmon calcitonin, Switzerland) was administrated according 
to the scheme, depending on the degree of osteogenic changes (100 IU 
per day intramuscularly every other day during the 1st month, 200 IU 
per day every day intranasal - 2nd and 3rd month). In parallel, patients 
received calcemin advance for 1 tablet 2 times per day for 3 months. 
The effectiveness of therapy with was evaluated after 3 months.
Data analysis
The results were analyzed using Statistica 7.0 software and presented 
as mean with SDs. To evaluate the distribution of the character together 
by sampling data, we have used Lilliefors and Kolmogorov–Smirnov 
tests. The differences between all groups were determined using 
one-way ANOVA, followed by post hoc least significant difference test. 
p<0.05 was considered statistically significant.
RESULTS
The analysis of the therapy effectiveness showed that standard therapy 
does not decrease bone resorption processes, and leads to loss of 
1.6% of bone mass in patients with normal BMD and 3.8% in patients 
with osteopenic changes. The results of the calcemin advance usage in 
patients with osteopenic changes showed a positive dynamics of the 
studied parameters, both in the lumbar spine and in the femoral bone. 
Thus, an additional therapy with calcemin advance in patients with 
CHF and osteopenia of different stage caused a statistically significant 
increase in BMD in the first two lumbar vertebrae with a simultaneous 
decrease in the manifestations of the toxic component and pain 
Table 1: BMD of lumbar vertebrae in patients with CHF and 
osteopenia, before and after therapy
Status L1 L2 L3 L4
2nd Group 
Before therapy 1.02±0.02 1.10±0.03 1.12±0.02 0.98±0.03
After therapy 0.96±0.02* 1.06±0.03 1.05±0.02* 1.02±0.03
3rd Group 
Before therapy 0.97±0.02 1.05±0.02 1.10±0.02 1.12±0.02
After therapy 1.05±0.03* 1.12±0.02* 1.14±0.02 1.15±0.02
Results are expressed as a mean and standard deviation. P<0.05 indicates 
significant differences. BMD: Bone mineral density, CHF: Chronic heart failure, 
L: Lumbar vertebrae
Table 2: BMD of femoral bone in patients with CHF and 
osteopenia, before and after therapy
Status Neck Ward triangle Trochanter Total
2nd Group 
Before therapy 0.92±0.02 0.82±0.03 0.89±0.03 1.04±0.02
After therapy 0.94±0.03 0.74±0.02* 0.90±0.03 1.04±0.03
3rd Group 
Before therapy 0.91±0.03 0.74±0.02 0.81±0.03 0.99±0.03
After therapy 0.94±0.03 0.82±0.03* 0.88±0.02* 1.00±0.03
Results are expressed as a mean and standard deviation. P<0.05 indicates 
significant differences. BMD: Bone mineral density, CHF: Chronic heart failure
Table 3: BMD of lumbar vertebrae in patients with CHF and 
osteoporosis, before and after therapy
Status L1 L2 L3 L4
4th Group 
Before therapy 0.81±003 0.85±0.03 0.92±0.03 0.94±0.03
After therapy 0.75±0.02 0.84±0.03 0.90±0.03 0.92±0.04
5th Group 
Before therapy 0.78±0.03 0.87±0.04 0.92±0.03 0.87±0.02
After therapy 0.87±0.02* 0.92±0.04 0.94±0.03 0.89±0.03
Results are expressed as a mean and standard deviation. P<0.05 indicates 
significant differences. BMD: Bone mineral density, CHF: Chronic heart failure, 
L: Lumbar vertebrae
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syndrome in the heart failure clinical manifestations (Table 1). Modified 
therapy with the inclusion of calcemin advance to standard therapy 
enhances bone mineralization in patients of 3rd Group in the femoral 
neck by 3.3%, in Ward’s triangle - by 10.8%, in greater trochanter - by 
8.6%, and in proximal femur - by 1.0% versus BMD indices in these 
patients before treatment (Table 2).
In patients with osteoporosis, the usage of osteoprotective therapy 
(calcemin advance+miacalcic) contributed to the increasing of BMD at 
L1 region by 16.0% (р<0.01), L2 - by 9.5% (р<0.05) versus patients who 
received only combined calcium with Vitamin D3 supplement (Table 3).
Modified therapy with the inclusion of calcemin advance and Miacalcic 
to standard therapy enhances bone mineralization in patients of 
5th Group in the femoral neck by 7.4%, in Ward’s triangle - by 11.1%, 
in greater trochanter - by 9.8%, and in proximal femur - by 8.1% versus 
BMD indices in patients of 4th Group who received only combined 
calcium with Vitamin D3 supplement (Table 4).
Furthermore, it should be noted that the rate of BMD reduction and its 
restoring with the use of osteoprotective therapy depends on the stage 
of osteodeficiency. Hence, in the presence of osteoporosis patients, 
lose more bone mass faster, but bone tissue faster is restored with the 
application of adequate treatment.
DISCUSSION
Osteoporosis is a systemic metabolic bone disease, which is 
characterized by decrease of bone mass, as well as degeneration of bone 
microstructure and is prone to lead to fracture due to increased bone 
fragility [16]. In Europe, osteoporosis accounts for more disability-
adjusted life years than many non-communicable diseases including 
rheumatoid arthritis, Parkinson’s disease, breast cancer, and prostate 
cancer [17]. Although plenty of studies on osteoporosis and CVDs have 
been carried out, there are still some controversies on the findings [18].
Our results and research made by Lewiecki and Silvermanhave indicated 
that bone micro-architectural changes associated with bone loss are 
largely irreversible [19,20]. Although treatment can increase BMD 
and reduce the risk of fracture, it is unlikely to fully restore the quality 
and strength of bone to normal. BMD in adults is determined by peak 
bone mass (PBM), which is the maximum bone mass achieved in life, 
and the subsequent rate of bone loss. The prevention of osteoporosis 
or low BMD is directed to maximizing PBM and minimizing the rate 
of bone loss, with the ultimate goal of maintaining bone strength and 
preventing fractures. Stabilizing BMD or reducing the rate of bone loss 
is the primary objective in the prevention of osteoporosis [20].
Li et al. suggested that patients with osteoporosis have a higher risk of 
CHD than those without osteoporosis. Patients who have osteoporosis 
and have received treatment with bisphosphonates have a significantly 
lower risk for CHD than those without treatment [21]. In the placebo 
branch of the MORE study, osteoporosis (T-score <−2.5 at the spine 
or the femoral neck) was associated with a fivefold higher risk of a 
cardiovascular event (for example, stroke and myocardial infarction). 
In a group of 6800 men and women (MONICA and Västerbotten 
Intervention Programme databases), low hip BMD was associated with 
a higher risk of myocardial infarction [22].
Potential mechanisms for the link between osteoporosis and CVD 
remain unknown. One hypothesis puts forth that the coexistence of 
osteoporosis and CVD is due to their shared etiological factors (such as 
smoking, physical activity, alcohol intake, menopause, and hypertension), 
which may simultaneously promote or inhibit atherosclerosis and bone 
demineralization. However, in many epidemiologic studies, the association 
between osteoporosis and CVD remained even after the adjustment 
of some of these risk factors. Second, common pathophysiological 
mechanisms are implicated in the progression of the two conditions: 
Inflammatory cytokines, endogenous sex hormones, oxidized lipids, 
Vitamin K deficiency, and Vitamin D. Third, the coexistence of osteoporosis 
and CVD may be due to common genetic factors. Genome-wide association 
studies have identified several genes and single nucleotide polymorphisms 
associated with BMD, and CVD risk factors or metabolic traits [23].
Calcium supplements marginally reduce the risk of fracture, and 
observational studies suggest that high calcium intake might protect 
against vascular disease, and the findings are consistent with those of 
interventional studies of calcium supplements that show improvement 
in some vascular risk factors [24]. On the another hand, calcification 
in the aorta and coronary arteries may increase cardiovascular risk 
through the activation of the bone morphogenetic protein, alkaline 
phosphatase, osteopontin, and matrix GLA protein [25].
CONCLUSIONS
Our results suggest that bone density screening could be recommended 
in patients with prevalent CHF. Moreover, the results of our investigation 
substantiate the necessity and effectiveness of osteoprotective therapy 
in patients with CHF with osteoporosis by calcitonin (Miacalcic), in 
combination with combined calcium and Vitamin D3 supplement 
(calcemin advance), and by only calcemin advance - in patients with 
CHF and osteopenia.
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